FDEV - ETF AI Analysis
Top Page
Fidelity International Multifactor ETF (FDEV)
FDEV (Fidelity International Multifactor ETF) has a solid overall rating driven mainly by high-quality global leaders like Novartis, AstraZeneca, ASML, and TotalEnergies, which bring strong financial performance, healthy balance sheets, and supportive earnings trends to the portfolio. The fund also benefits from attractively valued names such as Daito Construction and Klepierre, though some holdings like Shell, Roche, and Unilever face valuation and technical headwinds that can limit upside. A key risk is the ETF’s meaningful exposure to a few large international companies and sectors, which can increase sensitivity to sector-specific or regional market swings.
FDEV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 282.94M
- Region
- Developed Markets
- Expense Ratio
- 0.18%
- Beta
- 0.46
- Issuer
- Fidelity
- Inception Date
- Feb 26, 2019
- Dividend Yield
- 3.28%
- Asset Class
- Equity
- Index Tracked
- Fidelity International Multifactor Index
FDEV Summary
Fidelity International Multifactor ETF (FDEV) is an international stock fund that follows the Fidelity International Multifactor Index. It invests in companies across many countries, including Japan, the UK, the U.S., and more, and spreads money across sectors like financials, health care, energy, and consumer goods. Well-known holdings include Shell, Novartis, AstraZeneca, ASML, and Unilever. Investors might consider FDEV for broad global diversification in a single investment, with a strategy that aims to balance growth and stability. A key risk is that its value can rise or fall with global stock markets, and international stocks can be more volatile than U.S.-only funds.
How much will it cost me?
This ETF has an expense ratio of 0.18%, which means you’ll pay about $1.80 per year for every $1,000 invested. That’s lower than the average stock ETF because it’s a rules-based, passively managed multifactor fund rather than a fully active, stock-picking strategy.
What would affect this ETF?
This ETF focuses on developed markets outside the U.S. and spreads its investments across many sectors, so it could benefit if global growth strengthens, interest rates stabilize or fall, and large international companies in areas like health care, energy, and consumer goods continue to perform well. On the other hand, it could be hurt by slower economic growth abroad, rising interest rates that pressure financials and real estate, or new regulations and geopolitical tensions that weigh on major holdings such as Shell, Roche, Novartis, and ASML.
FDEV Top 10 Holdings
FDEV is leaning into a diversified mix of developed markets outside the U.S., with energy and health care quietly steering the ship. Shell and TotalEnergies have been rising, giving the fund a solid boost from the energy patch, while ASML’s strong year keeps a tech growth engine humming despite some recent mixed momentum. On the defensive side, Roche and Novartis are steady contributors, even as AstraZeneca’s weaker stretch and lagging names like Daito Construction and Klepierre slightly drag on returns. Overall, no single stock dominates, but sector tilts to energy and health care clearly shape performance.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GB:SHEL | Shell (UK) | 1.77% | $5.00M | GBP 224.83B | 39.66% | 73Outperform |
 JP:1878 | Daito Construction | 1.75% | $4.96M | JPY 1.06T | 0.52% | 73Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 SG:H78 | Hongkong Land Holdings | 1.65% | $4.68M | $17.72B | 36.17% | ―― |
 FR:LI | Klepierre (ex Compagnie Fonciere Klepierre) | 1.54% | $4.36M | EUR 9.98B | 6.18% | 72Outperform |
 CH:NOVN | Novartis AG | 1.46% | $4.12M | CHF 236.54B | 30.70% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 NL:ASML | ASML Holding NV | 1.46% | $4.13M | EUR 569.00B | 64.16% | 76Outperform |
 FR:TTE | TotalEnergies SE | 1.35% | $3.82M | EUR 186.61B | 56.32% | 78Outperform |
 TSE:CNQ | Canadian Natural | 1.30% | $3.67M | CAD 158.28B | 75.78% | 81Outperform |
FDEV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FDEV, the sentiment is Positive. The current price of 37.07 is above the 20-day moving average (MA) of 36.59, above the 50-day MA of 37.02, and above the 200-day MA of 36.05, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 54.62 is Neutral, neither overbought nor oversold. The STOCH value of 72.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDEV.
FDEV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FDEV | $37.07 | $39.00(5.21% Upside) | $282.94M | 0.18% | 64Neutral |
 FYLD | $40.13 | $43.69(8.88% Upside) | $750.84M | 0.59% | 62Neutral |
 TLTD | $100.04 | $116.53(16.48% Upside) | $662.34M | 0.39% | 65Neutral |
 TXUE | $34.71 | $39.92(15.02% Upside) | $580.67M | 0.65% | 64Neutral |
 MFDX | $41.17 | $49.95(21.34% Upside) | $451.99M | 0.39% | 64Neutral |
 AVSD | $79.19 | $91.06(14.98% Upside) | $374.80M | 0.23% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FDEV | Fidelity International Multifactor ETF | 37.07 | 5.09 | 15.92% | |
| FYLD | Cambria Foreign Shareholder Yield ETF | 40.13 | 9.88 | 32.64% | |
| TLTD | FlexShares Morningstar Developed Markets ex-US Factor Tilt | 100.04 | 13.68 | 15.84% | |
| TXUE | Thornburg International Equity ETF | 34.70 | 4.55 | 15.09% | |
| MFDX | PIMCO RAFI Dynamic Multi-Factor International Equity ETF | 41.17 | 5.09 | 14.11% | |
| AVSD | Avantis Responsible International Equity ETF | 79.19 | 9.05 | 12.90% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.